USO DE PORFIRINAS CATIÔNICAS COMO FOTOSSENSIBILIZADORES EM COMPOSIÇÕES PARA TRATAMENTO DE CÂNCER DE MAMA, PROCESSOS E PRODUTOS
Water-soluble cationic porphyrins [Sn(TE-3PyP)Cl2]Cl4 and [Au(TE-3PyP)]Cl5 address the limitations of existing breast cancer treatments by providing selective toxicity and reduced side effects through photodynamic therapy, effectively targeting triple-negative breast cancer cells.
Patent Information
- Application Number
- BR102025008434
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-04-29
- Publication Date
- 2026-11-10
AI Technical Summary
Current treatments for triple-negative breast cancer, such as chemotherapy and radiation therapy, lack selective toxicity and cause adverse effects on normal cells, while photodynamic therapy using existing photosensitizers like hematoporphyrin derivatives suffer from low solubility and prolonged photosensitivity issues.
Development of water-soluble cationic porphyrins, specifically [Sn(TE-3PyP)Cl2]Cl4 and [Au(TE-3PyP)]Cl5, as photosensitizing agents for photodynamic therapy, which are active at low molar concentrations and minimize impact on normal cells.
The porphyrins effectively target and destroy triple-negative breast cancer cells with minimal adverse effects on healthy tissues, offering a precise and controlled treatment method.
Smart Images

Figure 00000000_0000_ABST
Description
1 / 23 “USE OF CATIONIC PORPHYRINS AS PHOTOSENSITIZERS IN COMPOSITIONS FOR THE TREATMENT OF BREAST CANCER, PROCESSES AND PRODUCTS”
[01] The present technology deals with the use of eight water-soluble cationic porphyrins as photosensitizing agents in compositions for the treatment of breast cancer by means of photodynamic therapy. The porphyrin derivatives were active at low molar concentrations (less than 1 μM) for the “triple-negative” breast cancer cell line (MDA-MB-231). Among the porphyrins tested, the present technology reveals the porphyrins [Sn(TE-3PyP)Cl2]Cl4 and [Au(TE-3PyP)]Cl5 and their synthesis process.
[02] In 2022, 2.3 million diagnoses of female breast cancer were reported, with 670,000 deaths worldwide. Approximately 99% of breast cancers occur in women. Breast cancer is the second leading cause of death in cancer patients, accounting for approximately 24% of cancer-related cases.
[03] The MDA-MB-231 cell line is classified as a “triple-negative” breast cancer. This means that these cells do not express the estrogen receptor, the progesterone receptor, and the HER2 protein. This triple-negative breast cancer has an aggressive nature and resistance to hormonal therapies or treatments targeting the HER2 protein, which has limited the treatment options available for this subtype of the disease.
[04] Conventional treatments for breast cancer involve chemotherapy, radiation therapy, hormone therapy, targeted therapy, and surgery, or a combination thereof, depending on the extent, severity, and location of the cancer. In addition to emotional distress, several adverse effects have been reported for these treatments. Radiation therapy and Petition 870250034236, dated 04 / 29 / 2025, page 11 / 50 2 / 23 Chemotherapy is used as a first-line treatment for cancer, but it is characterized by a lack of selective toxicity, causing serious adverse effects such as inhibition of the immune response and myelosuppression. The antineoplastic agents currently used comprise substances with low molecular weight (less than 500 Da) that mostly affect the cell division process. Thus, they also affect dividing cells in normal tissue, such as cells of the digestive system, hair follicle cells, and immune system cells, causing the well-known side effects of chemotherapy.
[05] The evaluation of new substances, of natural or synthetic origin, with a lower potential for toxicity to normal cells, has been the main focus of research, opening perspectives for the identification of prototypes for the development of new, more effective pharmacological agents in cancer therapy.
[06] The use of photoactivated substances, which can act directly on cancer cells without affecting normal cells, has been evolving as an alternative strategy to conventional chemotherapy. This treatment, known as Photodynamic Therapy (PDT), involves the use of light-activated substances that will be used directly as a cytotoxic agent through various mechanisms. Photodynamic therapy stands out as an alternative cancer treatment because it consists of a localized and temporally controlled method, reducing potential adverse effects. The technique consists of administering a photosensitizer (PS) which, when irradiated with light in the presence of oxygen, produces cytotoxic reactive oxygen species, such as radical species and singlet oxygen, which, when interacting with cancer cells, lead to their destruction. As the reactive oxygen species generated in the process are highly Petition 870250034236, dated 04 / 29 / 2025, page 12 / 50 3 / 23 reactive and possessing short diffusion distances, it is possible to control the treatment's target location with high precision, mitigating the impact of the treatment on healthy areas of the body.
[07] In 1841, the extraction of hematoporphyrin from dried blood by removing iron marked the birth of photosensitizers, but it was only after the 1960s that work from various research groups appeared in the literature with data on the subject. Numerous scientists continued the search for new PS based on porphyrin derivatives, notably the work of Dougherty. He used hematoporphyrin derivatives for several years and paved the way that led to the first clinically approved PS formulation (called Photofrin® in some countries).
[08] In the constant search for producing ever better PS, several generations of substances have been obtained. The first group of PS, designated as the first generation of PS, comprises porphyrin macrocycles based on hematoporphyrin and its derivatives (HpD). Despite their photodynamic activity, they presented negative characteristics, since each formulation consisted of a mixture of oligomers that have absorptions around 630 nm, very low solubility in polar solvents, and give rise to prolonged photosensitivity in the patient. Porphyrin macrocycles allow structural modifications in the beta-pyrrolic and meso positions, in addition to the insertion of metallic cations in their central cavity through changes in synthetic methodologies, thus, they can lead to new substances with specific properties.
[09] PDT has several advantages over other traditional treatments: (i) it can be applied in locations where surgery is not an option, (ii) older patients and / or those vulnerable to surgery, chemotherapy or Petition 870250034236, dated 04 / 29 / 2025, page 13 / 50 4 / 23 radiotherapy can be treated with this modality, (iii) minor or non-existent adverse effects.
[10] Dabrowski, et al. (Dqbrowski, JM et al. Synthesis, photophysical studies and anticancer activity of a new halogenated water-soluble porphyrin. Photochemistry and photobiology, 83, 897-903, 2007.) developed a new halogenated water-soluble porphyrin as a photosensitizing agent for cancer treatment via photodynamic therapy. The porphyrin showed a significant photodynamic effect examined against MCF7 (human breast carcinoma), SKMEL 188 (human melanoma) and S91 (mouse melanoma) cell lines after red light irradiation.
[11] Sengupta, et al. (Sengupta D. et al. Benzamide porphyrins with directly conjugated and distal pyridyl or pyridinium groups substituted to the porphyrin macrocycles: Study of the photosensitizing abilities as inducers of apoptosis in cancer cells under photodynamic conditions. J. Photochem. Photobiol. B: Biol., 178, 228-236, 2018.) developed amphiphilic porphyrins as photosensitizing agents for the treatment of cancer via photodynamic therapy. The porphyrins showed better efficacy against the A549 cell line (human epithelial adenocarcinoma lung cancer) under in vitro photodynamic conditions compared to the MDA-MB-231 (breast cancer) and Pa-1 (ovarian cancer) cell lines.
[12] In the state of the art, water-soluble cationic porphyrins and their complexes with transition metals have not been found as photosensitizing agents for the treatment of breast cancer via photodynamic therapy. BRIEF DESCRIPTION OF THE FIGURES Petition 870250034236, dated 04 / 29 / 2025, page 14 / 50 5 / 23
[13] Figure 1 shows the chemical structure of porphyrin [H2(TE-3PyP)]Cl4 (1) and its complexes [Zn(TE-3-PyP)]Cl4 (2), [Mn(TE-3-PyP)]Cl5 (3), [Sn(TE-3-PyP)Cl2]Cl4 (4) and [Au(TE-3-PyP)]Cl5 (5).
[14] Figure 2 shows the absorption spectrum in the UV-Vis region of the intermediate porphyrin [Sn(T-3-PyP)(OH)2].
[15] Figure 3 shows the mass spectrum (MALDI-TOF MS) of the intermediate porphyrin [Sn(T-3-PyP)(OH)2].
[16] Figure 4 shows the 1H NMR spectrum (400 MHz, CDCh) of the intermediate porphyrin [Sn(T-3-PyP)(OH)2]. *Solvent impurities.
[17] Figure 5 shows the absorption spectrum in the UV-Vis region of porphyrin [Sn(TE-3-PyP)Cb]Cl4 (4).
[18] Figure 6 shows the mass spectrum (MALDI-TOF MS) of porphyrin [Sn(TE-3-PyP)Cl2]Cl4 (4).
[19] Figure 7 shows the 1H NMR spectrum (400 MHz, D2O) of porphyrin [Sn(TE-3-PyP)Cl2]Cl4 (4).
[20] Figure 8 shows the 119Sn NMR spectrum (149 MHz, D2O, SnMe4) of porphyrin [Sn(TE-3-PyP)Cl2]Cl4 (4).
[21] Figure 9 5 shows the absorption spectrum in the UV-Vis region of porphyrin [Au(TE-3-PyP)]Cl5 (5).
[22] Figure 10 shows the mass spectrum (ESI-MS) of porphyrin [Au(TE-3-PyP)]Cl5 (5).
[23] Figure 11 shows the 1H NMR spectrum (400 MHz, D2O) of porphyrin [Au(TE-3-PyP)]Cl5 (5).
[24] Figure 12 shows the chemical structures of the porphyrins [H2(T4TMAPP)]Cl4 (6), [Mn(T4TMAPP)Cl]Cl4 (7), [H2(T4SPP)] (8), [Mn(T4SPP)] (9), [H2(TB-3-PyP)]Cl4 (10) and [H2(TH-3-PyP)]Cl4 (11).
[25] Figure 13 shows the screening of cationic and anionic porphyrins for their cytotoxicity to breast cancer cells (MDA-MB). Petition 870250034236, dated 04 / 29 / 2025, page 15 / 50 6 / 23 231 and MCF-7) and non-tumor (HEK-293). Porphyrins were evaluated at a concentration of 10 μM for 72 hours. Viability was assessed by MTT assay.
[26] Figure 14 shows the activity of porphyrin derivatives on the clonogenic survival of MDA-MB-231 cells. The cells were treated with the substances at their respective IC50 values and exposed to green light (520 ± 5 nm) or not for 30 min and incubated for 14 days. Representative data from at least three experiments performed in triplicate.
[27] Figure 15 shows the effect of porphyrins on cell cycle progression of MDA-MB-231 cells. Cells were treated or not with porphyrins, irradiated for 30 min with green light and labeled with hypotonic fluorochrome solution containing propidium iodide and analyzed by flow cytometry. Data from two independent experiments in triplicate. DETAILED DESCRIPTION OF THE TECHNOLOGY
[28] The present technology deals with the use of eight water-soluble cationic porphyrins as photosensitizing agents in compositions for the treatment of breast cancer by means of photodynamic therapy. The porphyrin derivatives were active at low molar concentrations (less than 1 μM) for the “triple negative” breast cancer cell line (MDA-MB-231). Among the porphyrins tested, the present technology reveals the porphyrins [Sn(TE-3PyP)Cl2]Cl4 and [Au(TE-3PyP)]Cl5 and their synthesis process.
[29] More specifically, the present technology deals with the use of preparing medicines for the treatment of breast cancer. Petition 870250034236, dated 04 / 29 / 2025, page 16 / 50 7 / 23 cationic porphyrins defined by the structural formula what, J R =
[30] The porphyrins of the present technology can be used as photosensitizing agents in compositions for photodynamic therapy.
[31] In one embodiment of the technology, which is not limited, porphyrins may be complexed with transition metals, selected from the group comprising zinc, gold, tin and manganese. Furthermore, the metals may be linked to chloride and / or hydroxyl groups.
[32] The present technology reveals the cationic porphyrins [Sn(TE-3PyP)Cl2]Cl4 and [Au(TE-3-PyP)]Cl5, defined by the structural formulas Petition 870250034236, dated 04 / 29 / 2025, page 17 / 50 8 / 23 respectively.
[33] The process for the production of porphyrin [Sn(TE-3-PyP)Cl2]Cl4 comprises the following steps: a) Dissolve H2T-3-PyP in acidified water to a pH between 0 and 2 with HCl, to a final concentration of 2.5 to 3.0 mg.mL⁻¹ (porphyrin: acidified water); b) Subject the obtained mixture to magnetic stirring for 10-15 min at a temperature between 20 and 30°C; c) Add SnCb^hhO to that obtained in b so that the molar ratio of SnCl2:porphyrin is 3:1; d) Subject the obtained mixture to magnetic stirring for 2-3 hours at a temperature between 20 and 30 °C; e) Correct the pH of the solution obtained in d with an aqueous solution of NaOH until a pH between 8.0 and 8.5 is reached, obtaining a precipitate corresponding to the intermediate complex [Sn(T-3-PyP)(OH)2]; f) Purify the obtained sample using a short column chromatography system with neutral alumina and elute by increasing the polarity using dichloromethane (initially 100%), ethyl acetate (0-100%), and methanol (0-5%). Petition 870250034236, dated 04 / 29 / 2025, page 18 / 50 9 / 23 g) Solubilize the purified porphyrin [Sn(T-3-PyP)(OH)2] obtained in f in dimethylformamide (DMF), to a final concentration of 10 to 15 mg.mL-1 (porphyrin: DMF); h) Subject the sample obtained to magnetic stirring for 15-20 min at a temperature of 100 to 110°C; i) Add ethyl p-toluenesulfonate to the solution obtained in h so that the molar ratio of ethyl p-toluenesulfonate: [Sn(T-3-PyP)(OH)2] is 100:1; j) Subject the sample obtained to magnetic stirring for at least 24 hours at a temperature of 100 to 110°C; k) Add ethyl ether to the mixture obtained in j, to remove DMF and precipitate the alkylated porphyrin; l) Dissolve the alkylated porphyrin obtained in k with distilled water and proceed to remove the excess ethyl p-toluenesulfonate following the procedure below; m) Add a 3.0 to 3.5 mol.L-1 aqueous solution of ammonium hexafluorophosphate to the solution obtained in “l” until complete precipitation of the solid; n) Centrifuge the suspension obtained in “m” at 4000-5000 rpm and isolate the solid; o) Wash the solid with diethyl ether three times, centrifuge at 4000-5000 rpm and isolate the solid; p) Dissolve the solid obtained in “o” in acetone; q) Add a saturated solution of tetrabutylammonium chloride in acetone to the solution obtained in “p” to precipitate the porphyrin; r) Centrifuge the suspension obtained in “r” and isolate the solid; s) Wash the solid obtained in “r” with acetone three times, centrifuge at 4000-5000 rpm and isolate the solid; Petition 870250034236, dated 04 / 29 / 2025, page 19 / 50 10 / 23 t) Dry the solid in a desiccator containing silica gel for at least 24 hours under vacuum.
[34] The process for the production of porphyrin [Au(TE-3-PyP)]Cl5 comprises the following steps: a) Dissolve [H2(TE-3-PyP)]Cl4 in water, at a concentration of 3.4 to 4.0 mg.mL-1; b) Add LiCl to the solution obtained in such a way that the molar ratio of LiCl to porphyrin is 1:100; c) Adjust the pH of the medium to 11-11.5 with a 1.0 mol.L-1 aqueous solution of NaOH; d) Add KAuCU to that obtained in c so that the molar ratio of KAuCkporfin is 3:1; e) Subject the mixture obtained from magnetic stirring for 3-4 hours to a temperature between 20 and 30°C; f) Treat the material obtained in and with a 3.0 to 3.5 mol.L-1 ammonium hexafluorophosphate solution until complete precipitation of the gold complex; g) Centrifuge the suspension obtained in step “f” at 4000-5000 rpm and isolate the solid; h) Wash the solid obtained in “g” with diethyl ether three times, centrifuge at 4000-5000 rpm and isolate the solid; i) Dissolve the solid obtained in “h” in acetone; j) Precipitate the porphyrin contained in the solution obtained in “i” using a saturated solution of tetrabutylammonium chloride in acetone; k) Centrifuge the suspension obtained in “j” and isolate the solid; l) Wash the solid obtained in “k” with acetone three times, centrifuge at 4000-5000 rpm and isolate the solid; m) Dry the solid obtained in “l” in a desiccator containing silica gel under vacuum for at least 24 hours. Petition 870250034236, dated 04 / 29 / 2025, page 20 / 50 11 / 23
[35] Compositions for the treatment of cancer by photodynamic therapy using any of the eight porphyrins defined above are characterized by comprising at least one of the porphyrins selected from the group comprising [H2(TE-3-PyP)]Cl4 (1), [Zn(TE-3PyP)]Cl4 (2), [Sn(TE-3-PyP)Cl2]Cl4 (4), [Au(TE-3-PyP)]Cl5 (5), [H2(T4TMAPP)]Cl4 (6), [H2(T4SPP)] (8), [H2(TB-3-PyP)]Cl4 (10) and [H2(TH3-PyP)]Cl4 (11), and pharmaceutically acceptable excipients.
[36] The present invention can be better understood through the following examples, which are not limiting. EXAMPLE 1 - SYNTHESIS AND CHARACTERIZATION OF THE DERIVATIVE PORPHYRINIC [Sn(T-3-EPyP)Ch]Ch
[37] The complex [Sn(T-3-EPyP)Cb]Cl4 was obtained in two steps. The first step involved the metalation of the porphyrin 5,10,15,20-tetra(3-pyridyl)porphyrin, H2T-3-PyP, with tin salt according to a procedure adapted from Thomas (2016), giving rise to the intermediate porphyrin [Sn(T-3-PyP)(OH)2], which was subsequently alkylated following a procedure described by Batinic-Haberle (1999), Alenezi (2017) and Streit (2024), resulting in the final compound, the derivative [Sn(TE-3-PyP)Cl2]Cl4 (4).
[38] The first step began with the solubilization of the porphyrin H2T-3-PyP (150 mg: 0.24 mmol, 1 eq.) in 60 mL of water acidified with 1.0 M aqueous HCl solution (pH ~ 1) and the reaction mixture was kept under stirring for 10 minutes at 25 °C. The salt SnC^2H2O (165 mg: 0.73 mmol, 3 eq.) was added and the system was kept under stirring for 2 hours at 25 °C. The progress of the reaction was monitored by UV-Vis absorption spectroscopy and TLC using alumina as the stationary phase and ethyl acetate as the eluent. The reaction mixture was carefully neutralized with 1.0 M aqueous NaOH solution (pH ~ 8) to precipitate the intermediate complex [Sn(T-3-PyP)(OH)2]. In Petition 870250034236, dated 04 / 29 / 2025, page 21 / 50 Subsequently, dichloromethane was added to completely solubilize the metalloporphyrin, which was washed under exhaustive agitation with water five times. The organic fraction was passed through anhydrous sodium sulfate and the solvent was removed in a rotary evaporator. The crude product was purified by chromatography on a neutral alumina short column (5.0 cm), with gradient elution using dichloromethane, ethyl acetate, and methanol as eluents. The solvent from the fractions containing the product was removed in a rotary evaporator, resulting in a violet solid, which was solubilized in a minimal amount of dichloromethane and precipitated with cold hexane. The complex was filtered, washed with cold hexane, and incubated at 60 °C for 24 h. The product was obtained as a bright violet solid with a yield of 84% (164 mg).
[39] The product obtained was characterized by ultraviolet-visible (UV-Vis) absorption spectroscopy, matrix-assisted laser desorption / ionization mass spectrometry with time-of-flight analyzer (MALDI-TOF MS) using dihydroxybenzoic acid (DHB) as a matrix as shown, hydrogen nuclear magnetic resonance (1H NMR) and elemental analysis, as shown in Table 2. The characterizing data obtained are presented in Table 1 and the respective spectra in Figures 2-4. Table 1 - Characteristic data of porphyrin [Sn(T-3-PyP)(OH)2] UV-Vis (H2O) (m, 4H), 7.86 (m, J = 4.2 Hz, 4H). MALDI-TOF MS (MeOH / DHB) [M + DHB]'+, simulated in chemcalc software m / z = 924.146; experimental m / z = 924.264 C40H26N8O2Sn^2H2O; calculated: C (59.65%); Elemental analysis H (3.75%); N (13.91%); experimental: C (59.74%); H (3.81%); N (13.87%). Petition 870250034236, dated 04 / 29 / 2025, page 22 / 50 13 / 23
[40] The second step involved an ethylation reaction of porphyrin [Sn(T-3-PyP)(OH)2], a procedure carried out according to the method described in the literature by Batinic-Haberle (1999), Alenezi (2017) and Streit (2024).
[41] [Sn(T-3-PyP)(OH)2] (124.9 mg; 0.155 mmol, 1 eq.) and dimethylformamide (DMF) (10.0 mL) were added to a round-bottom flask and the system was maintained under magnetic stirring at 110 °C for 15 minutes. Then, ethyl p-toluenesulfonate (3.1086 g; 15.2 mmol, 100 eq.) was added to the system and the reaction was maintained for 24 hours under the conditions previously described. The conversion of the starting materials to the tetra-cationic product was monitored by TLC using SiO2 as the stationary phase and a mixture of KNO3(aq, sat):H2O:ACN (1:1:8) as eluent. Ethyl ether was used to remove the DMF from the reaction mixture, and the resulting solid was solubilized in 35 mL of water. Next, a few drops of aqueous ammonium hexafluorophosphate solution (3 mol L-1) were added until complete precipitation of the metalloporphyrin. The solid was isolated by centrifugation, washed three times with ethyl ether using a vortex mixer, and dried in an oven at 60 °C for at least one hour.The product with the PFe- counter-ion was solubilized in 30 mL of acetone, and a saturated solution of tetrabutylammonium chloride in acetone was added dropwise until complete precipitation of the metalloporphyrin. The solid was isolated by centrifugation and washed three times with acetone using a vortex mixer. The counter-ion exchange process was repeated until complete removal of the ethyl ptoluenesulfonate. The tin(IV) complex was obtained as a purple solid with an 80% yield (132 mg).
[42] The product obtained was characterized by absorption spectroscopy in the ultraviolet-visible (UV-Vis) region, mass spectrometry (MALDI-TOF MS) using dihydroxybenzoic acid (DHB) as Petition 870250034236, dated 04 / 29 / 2025, page 23 / 50 14 / 23 matrix, hydrogen nuclear magnetic resonance (1H NMR) and tin nuclear magnetic resonance (119Sn NMR) and elemental analysis. The data relating to the characterization of the derivative [Sn(T-3-EPyP)Cl2]Cl4 are presented below in Table 2, and the spectra resulting from the analyses are presented in Figures 5 to 8. Table 2 - Characterizing data of porphyrin [Sn(T-3-EPyP)Cl2]Cl4 UV-Vis (H2O) 4H), 5.21 (m, 8H), 2.8 (t, J = 7.0 Hz, 12H) 119Sn NMR (149 MHz, D2O, SnMe4, δ / ppm) -576.00 [M + 3DHB + 2H]2+ simulated by MALDI-TOF MS software (MeOH / DHB) chemcalc m / z = 763,089; experimental m / z = 762.984. C48H44Cl6N8Sn^6.50H2O; calculated: C Elementary analysis (48.80%); H (4.86%); N (9.48%); experimental: C (48.86%); H (4.63%); N (9.44%). EXAMPLE 2 - SYNTHESIS AND CHARACTERIZATION OF THE DERIVATIVE PORPHYRINIC [Au(TE-3-PyP)]Cl5
[43] The complex was prepared by adding 30 mL of an aqueous solution of [H2(TE-3-PyP)]Cl4 (101 mg, 0.12 mmol, 1 eq.) to 500 mg (12 mmol, 100 eq.) of LiCl. The pH of the medium was adjusted to 11 with 1 mol L-1 aqueous NaOH solution. KAuCk (0.34 mmol, 3 eq.) was dissolved in 10.00 mL of water and added dropwise to the system. The progress of the reaction was monitored by UV-Vis absorption spectroscopy and TLC using SiO2 as the stationary phase and a 1:1:8 KNO3(aq, sat):H2O:CH3CN mixture as eluent. The mixture was kept under magnetic stirring at 30 °C for 3 hours until complete conversion of Petition 870250034236, dated 04 / 29 / 2025, page 24 / 50 15 / 23 starting material, fluorescent, in the non-fluorescent complex [Au(TE-3-PyP)]Cl5 (5). The mixture was quantitatively transferred to a 50 mL Falcon tube, followed by the addition of a 3 mol L-1 aqueous solution of ammonium hexafluorophosphate. The suspension was filtered through a No. 4 sintered plate funnel and the yellowish filtrate was discarded. The dark red solid was washed thoroughly with ethyl ether to remove excess free salt and incubated at 60 °C for at least one hour. The solid was dissolved in acetone and precipitated with a saturated solution of tetrabutylammonium chloride in acetone. Subsequently, the light red solid was isolated by centrifugation, washed thoroughly with acetone using a vortex mixer, and incubated at 60 °C for 24 hours or until constant mass was obtained.The metathesis reaction with hexafluorophosphate and chloride ions, respectively, was repeated twice more to ensure the removal of excess gold salt. The bright red complex was obtained in 83% yield (106 mg) and characterized by UV-Vis electronic absorption spectroscopy, electrospray ionization mass spectrometry (ESI-MS), hydrogen nuclear magnetic resonance, and elemental analysis. Data relating to the characterization of the derivative [Au(TE-3-PyP)]Cl5 (5) (Figure 1) are presented below in Table 4, as well as the spectra resulting from the analyses, which are presented in Figures 9-11. Table - 3 Characteristic data of porphyrin [Au(TE-3-PyP)]Cl5 (5) UV-Vis (H2O) (s, 4H), 5.07 (s, 8H), 1.93 (s, 12H) ESI-MS (MeOH: H2O 9:1) [M - 4Cl + e-]4+ simulated chemcalc m / z: 232.33; experimental: m / z: 232.49 Elemental analysis C48H4áCl5N8Au^7.50 H2O; calculated: C Petition 870250034236, dated 04 / 29 / 2025, page 25 / 50 16 / 23 (46.41%); H (4.79%); N (9.02%); experimental: C (46.07%); H (4.70%); N (8.76%) EXAMPLE 3 - EVALUATION OF THE ANTITUMORAL ACTIVITY OF Water-soluble cationic porphyrin derivatives activated by green light.
[44] For cytotoxicity analysis of porphyrins, the MTT assay was used and, as an in vitro breast cancer model, MCF-7 cells (breast adenocarcinoma, negative for estrogen receptor), and MDA-MB-231 cells (breast adenocarcinoma, negative for estrogen and progesterone receptors) were used. As a non-tumor cell model, HEK-293 cells (a cell line derived from human embryonic kidney) were used for evaluation of nonspecific cytotoxicity. An initial screening of eleven porphyrins was performed - [H2(TE-3-PyP)]Ck(1), [Zn(TE-3- PyP)]Cl4 (2), [Mn(TE-3-PyP)]Cl5 (3), [Sn(TE-3-PyP)Cb]Cl4 (4) and [Au(TE-3PyP)]Cl5 (5), in addition to the porphyrins [H2(T4TMAPP)]Cl4 (6), [Mn(T4TMAPP)Cl]Cl4 (7), [H2(T4SPP)] (8), [Mn(T4SPP)] (9), [H2(TB-3PyP)]Cl4 (10) and [H2(TH-3-PyP)]Cl4 (11), whose chemical structures are shown in Figures 1 and 12. In the three cell lines, the porphyrins were tested at a concentration of 10 μM and those that inhibited viability by more than 50% had their IC50 determined.
[45] Cells were maintained in RPMI 1640 medium (Sigma Aldrich, USA) supplemented with 1% antibiotic solution (100 U / mL penicillin and 100 μg / mL streptomycin (GIBCO BRL, Grand Island, NY), enriched with 2 mM L-glutamine (GIBCO UK, Grand Island, NY) and 10% fetal bovine serum (GIBCO BRL, Grand Island, NY), and incubated in a 5% CO2 atmosphere at 37 °C. For solid tumor cells, 5% fetal bovine serum in DMEM (Sigma Aldrich, USA) was used. Petition 870250034236, dated 04 / 29 / 2025, p. 26 / 50 17 / 23 MB-231 and MCF-7 were used at concentrations of 5,000, 10,000, and 10,000 cells / well, respectively (96-well plates). All were incubated for 24 hours at 37 °C, 5% CO2 for stabilization. After this period, all cells were incubated with porphyrins for 24 hours in an atmosphere of 5% CO2 and 100% humidity at 37 °C. After 24 hours, the culture medium was replaced with complete medium without phenol red, and the cells were irradiated for 30 minutes with green light (green light / 10.11 mW cm-2 and 18.198 J cm-2). The medium was replaced again with complete medium with phenol red for 48 hours. During the irradiation of each plate, a control was performed under the same conditions, but in the absence of green light. The non-irradiated plate was kept in the dark in the incubator. The tests were performed in triplicate. A solvent (water) was used as a control at the same concentration as the samples tested.
[46] Cell proliferation and viability were assessed by the MTT assay, described below. The assay for assessing cell viability and proliferation is based on the metabolic reduction of 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan, and this assay allows the assessment of both cell proliferation and viability. The methodology used was described by Monks et al. (1991), and performed with modifications (Monks, A. et al., Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83, 757-766, 1991.). After the incubation period of the cells with the aforementioned porphyrins, 10 pL of a 2.5 mg / mL MTT solution (Sigma Aldrich, USA) in RPMI medium, prepared at the time of use, were added to each well (final volume of 100 pL).After 4 hours of incubation with the reagent and the consequent formation of formazan crystals, the supernatant was removed with a multichannel pipette in order to preserve the crystals. Subsequently, at each... Petition 870250034236, dated 04 / 29 / 2025, page 27 / 50 In wells 18 / 23, 100 µL of a 0.04 M HCl solution in isopropanol (Merk KGaA, Germany) was added. After solubilization of the formazam crystals generated by the metabolization of MTT by viable cells, the absorbance was quantified using a spectrophotometer at a wavelength of 595 nm.
[47] Results were expressed as percentage of inhibition compared to the PBS-containing control, calculated as follows: absorbances of control cells were considered to be zero percent. The percentage reduction in cell viability was calculated for treated cells by comparison with the PBS control. IC50 values were determined using nonlinear regression in the Prism 5.01 GraphPad program (GraphPad Software). The selectivity index (SI) was calculated to evaluate the antitumor potential and selectivity of water-soluble cationic porphyrin derivatives activated by green light. The SI was calculated by the ratio between the IC50 in HEK-293 cells divided by the IC50 of water-soluble cationic porphyrin derivatives activated by green light (520 ± 5 nm) in tumor cells (SI = IC50-HEK-293 / IC50-tumor cells). Screening experiments were performed in at least three independent experiments (triplicate).Active samples, which inhibited cell viability by less than or equal to 50%, were sent for IC50 determination.
[48] Of the eleven substances tested, eight reduced the viability of MDA-MB-231 and MCF-7 cells by more than 50%: [H2(TE-3-PyP)]Cl4 (1), [Zn(TE-3-PyP)]Cl4 (2), [Sn(TE-3-PyP)Cb]Ck (4) and [Au(TE-3-PyP)]Cl5 (5), [H2(T4TMAPP)]Cl4 (6), [H2(T4SPP)] (8), [H2(TB-3-PyP)]Cl4 (10) and [H2(TH3-PyP)]Cl4 (11) in the presence of green light / 30min, but were not active in the absence of green light (Figure 13). Petition 870250034236, dated 04 / 29 / 2025, page 28 / 50 19 / 23
[49] The IC50 values presented in Table 4 show that seven porphyrins presented IC50 values at nanomolar concentration, highlighting [H2(T4TMAPP)]Cl4 (6) (0.007 μM) and [H2(TH-3-PyP)]Cl4 (11) (0.03 μM). All compounds were inactive in the absence of green light up to a concentration of 1mM (>1000 μM). The porphyrin [H2(T4TMAPP)]Cl4 (6) showed the best result for MDAMB-231 cells (IS = 13) followed by [H2(TB-3-PyP)]Cl4 (10) (IS = 5). For MCF7 the IS values were 9 and 13 for [H2(T4TMAPP)]Cl4 (6) and [H2(TB3-PyP)]Cl4 (10), respectively. Table 4 - Determination of the 50% inhibitory concentration (IC50, in μM) of cell viability of MDA-MB-231 and HEK-293 cells treated with water-soluble cationic and anionic porphyrin derivatives [H2(TE-3-PyP)]Cl4 (1), [Zn(TE-3-PyP)]Cl4 (2), [Sn(TE-3-PyP)Cl2]Cl4 (4) and [Au(TE-3-PyP)]Cl5 (5), [H2(T4TMAPP)]Cl4 (6), [H2(T4SPP)] (8), [H2(TB-3PyP)]Cl4 (10) and [H2(TH-3-PyP)]Cl4 (11)), in the presence or absence of green light (520 ± 5 nm). Data are presented with IC50 values. with their respective confidence intervals (CI). MDA-MD-231 MCF-7 HEK-293 Porphyrin Light IS* No light Light IS* No light Light No light 0.21 0.17 0.68 1 (0.11 to 3 >1000 (0.01 to 4.0 >1000 (0.56 to >1000 0.36) 0.26) 0.78) 0.22 0.07 0.12 2 (0.09 to 0.5 >1000 (0.01 to 1.7 >1000 (0.09 to >1000 0.41) 0.16) 0.18) 0.77 0.15 0.13 4 (0.50 to 0.2 >1000 (0.11 to 0.9 >1000 (0.04 to >1000 0.10) 0.19) 0.40) 25.24 16.81 44.73 5 (15.25 to 1.8 >1000 (5.97 to 2.7 >1000 (25.31 to >1000 42.36) 53.49) 86.39) 0.007 0.01 0.09 6 (0.006 to 13 >1000 (0.007 to 0.01) 9.0 >1000 (0.0007 to >1000 0.009) 0.49) Petition 870250034236, dated 04 / 29 / 2025, page 29 / 50 20 / 23 8 0.95 0.97 (0.28 to 3.36) 1.2 1.19 (0.66 to 1.14) 1.2 >1000 >1000 (0.62 to 2.92) >1000 0.13 0.048 0.63 10 (0.04 to 5 >1000 (0.01 to 13.0 >200 (0.16 to >1000 0.40) 0.23) 2.84) 0.03 0.006 0.006 11 (0.009 to 0.2 >1000 (0.0009 to 1.0 >1000 (0.003 to >1000 0.098) 0.023) 0.01) *IS: Calculated by the ratio between the IC50 of non-tumor cells and tumor cells (IC50 HEK-293 / IC50 MDA-MB-231 or MCF-7) EXAMPLE 4 - CLONOGENICITY TEST
[50] The clonogenic or colony-forming assay allows the detection of cells that retained the ability to generate offspring after treatment with a chemotherapeutic agent that was able to induce cell division-associated death. These substances were evaluated in the clonogenic assay at their respective IC50 values, which allows predicting the clinical efficacy of promising substances in the treatment of a disease.
[51] The clonogenicity assay was performed as previously described by Fiebig (2004) (Fiebig, HH et al. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer, 40, 6, 802-820, 2004.). MDA-MB-231 cells were cultured in complete medium with phenol red in six-well plates at a density of 400 cells per well for 3 hours to allow adhesion. They were then treated with porphyrin derivatives for 16 hours and the culture medium with phenol red was replaced with a medium supplemented without phenol red, followed by irradiation with green light (520 ± 5 nm) for 30 min. After irradiation, the complete medium without Petition 870250034236, dated 04 / 29 / 2025, page 30 / 50 21 / 23 phenol red was replaced with fresh phenol red medium, and the cells were incubated for 14 days. After incubation, the wells were washed with PBS, and the cells were fixed with paraformaldehyde (700 pL / well) for 30 min and stained with crystal violet (700 pL / well) for 30 min. For each plate subjected to green light irradiation for 30 minutes, a control plate was prepared and kept in the dark for 30 minutes inside the incubator for comparison. At least three independent experiments were performed in triplicate. The number of colonies, the survival fraction, and the plating efficiency were then determined. The survival fraction took into account the number of cells plated and the plating efficiency.
[52] In Figure 14, it is possible to observe that the treatment of MDA-MB-231 cells with the water-soluble porphyrin derivatives 1, 2, 4, 5, 6, 8, 10 and 11, at their respective IC50 values, significantly reduced the survival of clonogenic cells compared to the control. It is also observed that porphyrin derivatives 4, 10 and 11 were the most active and completely reduced the clonogenic survival of MDA-MB231 cells when subjected to green light for 30 minutes. These derivatives showed better activity when used at the concentrations corresponding to their respective IC50 values, with a 100% reduction in colonies when compared to the other substances tested. Substances 1 and 2 inhibited colony survival by approximately 50%, while compounds 5, 6 and 8 inhibited it by approximately 30%.The data clearly indicate that the observed effect is dependent on irradiation with green light, since MDA-MB-231 cells treated with porphyrin derivatives 1, 2, and 4, but not irradiated, maintained colony growth identical to the control (autoclaved MilliQ water, used to solubilize the substances). Compounds 5, 6, 8, 10, and 11, however, showed activity in the absence of light. Petition 870250034236, dated 04 / 29 / 2025, page 31 / 50 22 / 23 in relation to the control, suggesting lower selectivity of these substances. Figure 14 shows representative images in the upper panel of MDA-MB-231 cell colonies in the presence and absence of light (control) and below the quantification of the number of colonies in relation to the control culture (Figure 14). EXAMPLE 5 - EVALUATION OF THE CELL CYCLE BY HFS (HYPOTONIC FLUOROCHROMIC SOLUTION) IN MDAMB-231 CELLS
[53] This assay allows the evaluation of the cell cycle and the identification of its phases, as well as the subdiploid DNA content that is associated with apoptotic death, among others. The Riccardi & Nicoletti (2006) protocol was used. (Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc., 1, 1458- 1461,2006.)
[54] In summary, MDA-MB-231 cells were plated in 24-well plates (360 µl / well) using complete DMEM medium, at a density of 60,000 cells / well. After 24 h, the cells were treated with porphyrins at the same concentration (0.3 µM) for initial comparison of potency between the porphyrins. After 24 h of treatment, the culture medium was replaced with complete medium supplemented without phenol red (300 µl) and irradiation was performed with green light, 520 ± 5 nm, for 30 min. The culture medium was replaced with complete DMEM medium and the plates were incubated for another 48 h. For each irradiated plate, a control plate (not irradiated) was kept in the dark of the incubator for 30 minutes during the irradiation of the treated plate. After 48 hours, the supernatant was removed and transferred to the cytometry tube.The plate was washed with 200 μL of PBS, trypsinized with 100 μL of trypsin, and neutralized with 300 μL of supplemented DMEM, with all of this content being transferred to the cytometry tube. After this process was completed... Petition 870250034236, dated 04 / 29 / 2025, page 32 / 50 23 / 23 the tubes were centrifuged and the supernatant was aspirated. To break up the sediment at the bottom of the tubes, a vortex mixer was used. Next, hypotonic fluorochrome solution (HFS) containing propidium iodide (PI) was added, followed by incubation for one hour. After incubation, cell cycle analysis was performed using a cytometer, where it was possible to identify and quantify cells by size and granularity in different phases of the cell cycle, namely sub-G0 / G1, G0 / G1 and G2 / M. In this method, the increase in cells in the sub-G0 / G1 phase (subdiploid content) may be related to nuclear fragmentation due to apoptosis or late necrosis.
[55] In the data presented in Figure 15 it is possible to observe that of the eight porphyrins analyzed, three of them (6, 10 and 11) induced a significant increase in subiploid DNA content (about 10%) compared to the control. In addition, a significant reduction in the G0 / G1 and G2 / M phases induced by porphyrin 10 was also observed.
[56] Analysis of the data indicates that porphyrins 6, 10 and 11 can interfere with cell cycle progression by inducing DNA fragmentation, thus suggesting a pro-apoptotic effect, an effect known as one of the mechanisms of action of anticancer drugs. Petition 870250034236, dated 04 / 29 / 2025, page 33 / 50
Claims
1 / 5 CLAIMS 1. USE OF CATIONIC PORPHYRINS defined by structural formula J characterized as being for preparing medicaments for the treatment of breast cancer.
2. USE, according to claim 1, characterized by being as photosensitizing agents in compositions for photodynamic therapy.
3. USE, according to any one of claims 1 and 2, characterized by the porphyrins being complexed with transition metals selected from the group comprising zinc, gold, tin and manganese.
4. USE, according to claim 3, characterized in that the metals are bonded to chloride and / or hydroxyl groups.
5. CATIONIC PORPHYRIN, as defined in claim 4, characterized by being the porphyrin [Sn(TE-3-PyP)Cl2]Cl4, defined by the structural formula 6. CATIONIC PORPHYRIN, as defined in claim 4, characterized by being the porphyrin [Au(TE-3-PyP)]Cl5, defined by the structural formula Petition 870250034236, dated 04 / 29 / 2025, page 35 / 50 3 / 5 7. PROCESS FOR THE PRODUCTION OF PORPHYRIN defined in claim 5, characterized by comprising the following steps: a) Solubilizing H2T-3-PyP in water acidified to pH between 0 and 2 with HCl, to a final concentration of 2.5 to 3.0 mg.mL1 (porphyrin: acidified water); b) Subject the obtained sample in a to magnetic stirring for 10-15 min at a temperature between 20 and 30°C; c) Add SnC^2H2O to the obtained sample in b so that the molar ratio of SnC^2H2O to porphyrin is 3:1; d) Subject the obtained sample in c to magnetic stirring for 2 to 3 hours at a temperature between 20 and 30°C; e) Correct the pH of the obtained sample in d with an aqueous solution of NaOH until reaching a pH between 8.0 and 8.5, obtaining a precipitate corresponding to the intermediate complex [Sn(T-3-PyP)(OH)2]; f) Purify the obtained sample in e on a short neutral alumina chromatographic column and elute by increasing the polarity using initially 100% dichloromethane and a gradient of ethyl acetate, from 0 to 100%, and methanol, from 0 to 5%; g) Solubilize the purified porphyrin [Sn(T-3-PyP)(OH)2] obtained in f in dimethylformamide (DMF), to a final concentration of 10 to 15 mg.mL-1 (porphyrin: DMF); h) Subject the obtained mixture to magnetic stirring for 15 to 20 min at a temperature of 100 to 110°C; i) Add ethyl p-toluenesulfonate to the obtained mixture in h so that the molar ratio of ethyl p-toluenesulfonate: [Sn(T-3-PyP)(OH)2] is 100:1; j) Subject the obtained mixture to magnetic stirring for at least 24 hours at a temperature between 100-110°C; Petition 870250034236, dated 04 / 29 / 2025, page 36 / 50 4 / 5 k) Add ethyl ether to the obtained mixture in j, to remove DMF and precipitate the alkylated porphyrin; l) Dissolve the alkylated porphyrin obtained in k with distilled water and remove the excess ethyl p-toluenesulfonate following the procedure below; m) Add a 3.0 to 3.5 mol aqueous solution of ammonium hexafluorophosphate.L-1 in the solution obtained in “l” until complete precipitation of the solid; n) Centrifuge the suspension obtained in “m” at 4000-5000 rpm and isolate the solid; o) Wash the solid with diethyl ether three times, centrifuge at 4000-5000 rpm and isolate the solid; p) Dissolve the solid obtained in “o” in acetone; q) Add a saturated solution of tetrabutylammonium chloride in acetone to the solution obtained in “p” to precipitate the porphyrin; r) Centrifuge the suspension obtained in “r” and isolate the solid; s) Wash the solid obtained in “r” with acetone three times, centrifuge at 4000-5000 rpm and isolate the solid; t) Dry the solid in a desiccator containing silica gel for at least 24 hours under vacuum.
8. PROCESS FOR THE PRODUCTION OF PORPHYRIN defined in claim 6, characterized by comprising the following steps: a) Solubilizing [H2(TE-3-PyP)]Cl4 in water, at a concentration of 3.4 to 4.0 mg.mL-1; b) Adding LiCl to the obtained solution so that the molar ratio of LiCl:porphyrin is 1:100; c) Adjusting the pH of the medium to 11-11.5 with a 1.0 mol.L-1 aqueous solution of NaOH; d) Adding KAuCl4 to the obtained solution so that the molar ratio of KAuCl4 / porphyrin is 3:1; e) Subject the obtained mixture to magnetic stirring for 3 to 4 hours at a temperature between 20 and 30°C; f) Treat the obtained mixture with a 3.0 to 3.5 mol ammonium hexafluorophosphate solution.L-1 until complete precipitation of the gold complex; g) Centrifuge the suspension obtained in “f” at 4000-5000 rpm and isolate the solid; h) Wash the solid obtained in “g” with diethyl ether three times, centrifuge at 4000-5000 rpm and isolate the solid; i) Solubilize the solid obtained in “h” in acetone; j) Precipitate the porphyrin contained in the solution obtained in “i” using a saturated solution of tetrabutylammonium chloride in acetone; k) Centrifuge the suspension obtained in “j” and isolate the solid; l) Wash the solid obtained in “k” with acetone three times, centrifuge at 4000-5000 rpm and isolate the solid; m) Dry the solid obtained in “l” in a desiccator containing silica gel under vacuum for at least 24 hours.
9. COMPOSITIONS FOR THE TREATMENT OF CANCER BY PHOTODYNAMIC THERAPY using the porphyrins defined in any of the preceding claims, characterized by comprising at least one of the porphyrins selected from the group comprising [H2(TE-3-PyP)]Cl4 (1), [Zn(TE-3-PyP)]Cl4 (2), [Sn(TE-3PyP)Cl2]Cl4 (4), [Au(TE-3-PyP)]Cl5 (5), [H2(T4TMAPP)]Cl4 (6), [H2(T4SPP)] (8), [H2(TB-3-PyP)]Cl4 (10) and [H2(TH-3-PyP)]Cl4 (11), and pharmaceutically acceptable excipients. Petition 870250034236, dated 04 / 29 / 2025, pages 38 / 50
